Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 21 other studies
people with dyslipidemia, in this paper
The trial randomly assignedassigned by chance
atorvastatin
placebo
Probably reduced non-fatal myocardial infarction and fatal coronary heart disease events−19%
Probably reduced total coronary events−12%
Probably reduced CV deaths−14%
randomisedthe abstract, start to end
… heart disease (CHD) events (HR (95% CI) 0.81 (0.69 to 0.94, p=0.006)), total coronary events (0.88 (0.80 to 0.98, p=0.017)) and CV deaths (0.86 (0.74 to 0.99, p=0.048)).
← favours treatmentfavours comparator →
could be chanceNon-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD) eventsatorvastatin vs placebo
HR 0.810.69–0.94
Total coronary eventsatorvastatin vs placebo
HR 0.880.80–0.98
CV deathsatorvastatin vs placebo
HR 0.860.74–0.99
StatinsCardiovascular events
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
1 / 6